Clinical trial
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary…
NCT03759379 · Alnylam Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03759379 |
|---|---|
| Title | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) |
| Official title | HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) |
| Lead sponsor | Alnylam Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Amyloidosis, Hereditary, Transthyretin Amyloidosis |
| Intervention type | Drug |
| Interventions | Patisiran, Vutrisiran |
| Enrollment | 164 |
| Start date | Feb 14, 2019 |
| Primary completion | Nov 10, 2020 |
| Completion | Nov 5, 2025 |
| First posted | Nov 30, 2018 |
| Last update posted | Jan 12, 2026 |
| Countries | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Greece, Italy, Japan and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: